EBITDA for Q2FY26 was reported at Rs 23.60 crore

Hester Biosciences has reported consolidated net profit of Rs 14.33 crore for the Q2 FY25-26, rise of 71 per cent as compared to the net profit of Rs 8.39 crore reported in the second quarter of FY 2024-25. Revenue from operations of the company for the Q2FY26 was reported at Rs 70.97 crore. EBITDA for Q2FY26 was reported at Rs 23.60 crore (EBITDA margin 33 per cent) as against EBITDA of Rs 21.96 crore (EBITDA margin 26 per cent) in Q2FY25. EPS for Q2 FY26 was Rs 16.85 per share. Consolidated results include operations of subsidiaries from Nepal and Tanzania.

Net Profit for H1 FY26 was reported at Rs 31.63 crore, up 99 per cent Y-o-Y from Rs 15.88 crore in the corresponding period last year. EBITDA for H1FY26 was reported at Rs 49.78 crore (EBITDA margin 32 per cent) as against EBITDA of Rs 41.69 crore (EBITDA margin 25 per cent) in Q2FY25. For H1 FY26, company reported revenue of Rs 155.07 crore. The company maintained strong operational discipline, through controlled overheads, process standardisation, and efficient manpower deployment. The focus remains on margin protection and cost optimisation, while positioning for an expected recovery in volumes during the second half of the year.

Hester Africa reported a net profit of Rs 4.82 crore in Q2 FY26 and Rs 10.32 crore in H1 FY26, on toplines of Rs 5.99 crore and Rs 23.22 crore, respectively. Profit growth was supported by improved operational discipline and favourable foreign exchange movements. However, order flows across certain geographies remain subdued due to delays in project approvals and political transitions. The company expects market conditions to stabilise and institutional demand to recover over the next few quarters.